Plenary Session Will Unveil Impact of Non-Tobacco Factors in Lung Cancer Risk
Fred GebhartPresentations will look beyond tobacco to address how exposure to other environmental hazards may play a role in the development of lung cancer. Read more
Lung Cancer Beyond Smoking: Outdoor Air Pollution and Lung Cancer
Haleigh BehrmanDr. Joan H. Schiller will discuss the impact the environment has on cancer care and outcomes. Read more
Surgical Challenges and Opportunities in Locally Advanced NSCLC
Haleigh BehrmanDr. Brendon Stiles will explore the controversial topic of “converting” patients who are considered unresectable into surgical candidates. Read more
Second Presidential Symposium to Focus on Latest in Targeted Therapy Research
Fred GebhartPresentations will include data from the POLESTAR, SOHO-01, Beamion LUNG-1, FURTHER, and FLOWERS trials. Read more
Challenging Patient Outcomes Can Cause Oncologists to Question Their Skills
Fred GebhartDuring a Health & Wellbeing session, Dr. Mark Lewis will offer strategies for navigating such situations. Read more
Meet the Expert: Radiological Challenges in Lung Cancer
Erin JungmeyerDr. Ioannis Vlahos will address issues radiologists encounter in applying TNM staging guidelines in daily practice. Read more
Self-Learning AI as a Diagnostic Tool in Malignant Mesothelioma
Erin JungmeyerProf. John Le Quesne will show how AI can be used to subtype mesothelioma into risk categories and prognosis. Read more
IASLC Journals See Continued Success Throughout Past Year
Bailey CreamerEditors-in-Chief Drs. Alex A. Adjei and Emily Stone will talk with members during a Meet-the-Editor session on Monday afternoon. Read more
Hands-on Workshop Outlines Challenges and Potential Solutions for Translating Early Detection Biomarkers From Discovery to Lung Cancer Clinical Practice
Krithika Subramanian, PhDAn expert panel from the US National Cancer Institute’s Early Detection Research Network provided insights into the current state of the art as well as barriers to use. Read more
Updated Biomarker Survey Results Show Paradigm Shift As More Respondents Now Consider Testing a “Must Have”
Fred GebhartHowever, lead author Dr. Matthew Smeltzer said the new data also show clinicians value biomarker testing more in late-stage disease compared to early-stage disease. Read more